The impact of misspecification of residual error or correlation structure on the type i error rate for covariate inclusion

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 36, Issue 1, 2009, Pages 81-99

  Silber, Hanna E ^a   Kjellsson, Maria C ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Categorical data; Continuous data; Likelihood ratio test; Markov model; Model misspecification; NONMEM; Proportional odds model; Residual error; Simulation

Indexed keywords

ANALYTICAL ERROR; ARTICLE; COMPARTMENT MODEL; HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SIMULATION;

ALGORITHMS; BIAS (EPIDEMIOLOGY); COMPUTER SIMULATION; EPIDEMIOLOGIC RESEARCH DESIGN; LIKELIHOOD FUNCTIONS; MARKOV CHAINS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHARMACOKINETICS; PHARMACOLOGY; RESEARCH DESIGN; STATISTICS, NONPARAMETRIC;

EID: 61449165658     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-009-9112-1     Document Type: Article

References (19)

1. MO Karlsson SL Beal LB Sheiner 1995 Three new residual error models for population PK/PD analyses J Pharmacokinet Biopharm 23 651 672 10.1007/BF02353466
2. Users Guides, NONMEM In: Beal SL, Sheiner LS (eds) Icon Development Solutions, Elliot City, Maryland, USA
3. U Wahlby EN Jonsson MO Karlsson 2001 Assessment of actual significance levels for covariate effects in NONMEM J Pharmacokinet Pharmacodyn 28 231 252 10.1023/A:1011527125570
4. U Wahlby MR Bouw EN Jonsson MO Karlsson 2002 Assessment of type I error rates for the statistical sub-model in NONMEM J Pharmacokinet Pharmacodyn 29 251 269 10.1023/A:1020254823597
5. S Jonsson MC Kjellsson MO Karlsson 2004 Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM and NLMIXED J Pharmacokinet Pharmacodyn 31 299 320 10.1023/B:JOPA.0000042738.06821. 61
6. Kjellsson MC, Zingmark PH, Jonsson EN, Karlsson MO (2005) A study comparing the performance of the proportional odds model to that of the differential drug effect model for cumulative logits. Abstract 780, p 14, www.page-meeting.org/?abstract=780
7. V Murphy A Dunne 2005 Mixed effects versus fixed effects modelling of binary data with inter-subject variability J Pharmacokinet Pharmacodyn 32 245 260 10.1007/s10928-005-0045-z
8. I Yano SL Beal LB Sheiner 2001 The need for mixed-effects modeling with population dichotomous data J Pharmacokinet Pharmacodyn 28 389 412
9. S Chabaud P Girard P Nony JP Boissel 2002 Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris J Pharmacokinet Pharmacodyn 29 339 363 10.1023/A: 1020953107162
10. MO Karlsson RC Schoemaker B Kemp AF Cohen JM van Gerven B Tuk CC Peck M Danhof 2000 A pharmacodynamic Markov mixed-effects model for the effect of temazepam on sleep Clin Pharmacol Ther 68 175 188 10.1067/mcp.2000.108669
11. PH Zingmark M Kagedal MO Karlsson 2005 Modelling a spontaneously reported side effect by use of a Markov mixed-effects model J Pharmacokinet Pharmacodyn 32 261 281 10.1007/s10928-005-0021-7
12. M Davidian DM Giltinan 1993 Some general estimation methods for nonlinear mixed-effects models J Biopharm Stat 3 23 55 10.1080/10543409308835047
13. MO Karlsson EN Jonsson CG Wiltse JR Wade 1998 Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients J Pharmacokinet Biopharm 26 207 246 10.1023/A:1020561807903
14. NONMEM UsersNet Archive (2008) [NMusers] WRES and outlier identification/exclusion. http://www.cognigencorp.com/nonmem/nm/99sep252006. html. Accessed April 6
15. MO Karlsson LB Sheiner 1993 The importance of modeling interoccasion variability in population pharmacokinetic analyses J Pharmacokinet Biopharm 21 735 750 10.1007/BF01113502
16. PO Gisleskog MO Karlsson SL Beal 2002 Use of prior information to stabilize a population data analysis J Pharmacokinet Pharmacodyn 29 473 505 10.1023/A:1022972420004
17. Kjellsson MC, Ouellet D, Miller R, Karlsson MO (2007) Modelling sleep using markov mixed effects models. Abstract 1158, p 16, www.page-meeting.org/? abstract=1158
18. EN Jonsson MO Karlsson 1999 Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM Comput Methods Programs Biomed 58 51 64 10.1016/S0169-2607(98)00067-4
19. AC Hooker CE Staatz MO Karlsson 2007 Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method Pharm Res 24 2187 2197 10.1007/s11095-007-9361-x